PDCD1 and cancer: Similarly, while anti-TIGIT antibodies have shown remarkable effectiveness in treating solid tumors, the dual blockade of PD-1 and TIGIT has demonstrated superior clinical benefits in cancer treatment (Smith et al., 2013; Tedelind et al., 2007; Høgh et al., 2020).